The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses

摘要: Background This year marks the twentieth anniversary of approval by US Food and Drug Administration interleukin-2 (IL2) for use in cancer therapy, initially renal cell carcinoma later melanoma. IL2 therapy has stood test time, with continued widespread Europe, parts Asia, US. Clinical complete responses are variably reported at 5%-20% advanced malignant melanoma carcinoma, strong durable sustained long-term 5-10-year survival being typical if generated. Methods The literature was reviewed actions clinical effects on subsets T cells. influence efficacy also sought. Results review revealed that is capable stimulating different populations cells humans to induce either effector or regulatory responses. apparent "functional paradox" confounded a clear understanding mechanisms behind observed during following administration therapy. An average response rate around 7% small large trials using been shown from recent literature. Conclusion considers published concerning emerging spanning its 20-year period use. It further details some recently described "bimodal" explain functional paradox, how might be harnessed emerge rapidly as much more effective predictable agent near future.